You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
1.00 / AMA PRA Category 1 Credit(s)TM
There is a clear treatment gap in the approach to dyslipidemia in the primary care setting. Busy primary care providers often do not diagnose, or delay in the diagnosis of dyslipidemia, leaving people at increased cardiometabolic risk for some time. Once they do make the diagnosis, they often fail to be aggressive enough in achieving therapeutic goals, and often focus only on total or LDL cholesterol and miss the residual risk imparted by other lipid fractions. This activity seeks to address these gaps. The activity, through varied modalities and non-educational interventions, will cover multiple key topics crucial to improving the knowledge-base of PCPs, including: the significance of dyslipidemia in the context of the cardiometabolic syndrome and lipid metabolism; and diagnostic criteria for dyslipidemia. Ultimately, we will outline treatment recommendations for this condition, with an emphasis on achievement of therapeutic goals. The goal will be to overcome clinical inertia, so practitioners treat in a timely manner and achieve recommended therapeutic targets. As a mechanism for doing so, we will provide suggestions on methods to develop a lipid management program within the clinical practice.
Primary care providers (MD, DO, NP, PA)
Specialists in medical areas other than Lipidology (Endocrinology, Nephrology, Cardiology) who see significant numbers of people with dyslipidemia. Certified Diabetes Educators.
After taking part in this educational activity, participants should be better able to:
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non–healthcare-related companies, which are exempt.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
CME Advisory Committee
Dr. Richard S. Beaser,* Medical Executive Director, Professional Education, Joslin Diabetes Center, is a consultant for AstraZeneca/Bristol-Myers Squibb Company and CeQur LTD.
Julie A. Brown,* Director, Professional Education, Joslin Diabetes Center, is a consultant for AstraZeneca/Bristol-Myers Squibb Company.
Dr. Enrique Caballero, Director, Medical Affairs, Professional Education, Director, Latino Diabetes Initiative, Joslin Diabetes Center, is a consultant and on the speakers bureau and scientific advisory board for Amylin Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., and Eli Lilly and Company.
Dr. Jerry Cavallerano, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
Dr. A. Patrick Egan, Family Practice, Internal Medicine Specialist, Dorchester House Multi-Service Center, has no relevant financial relationships.
Anne E. Goebel-Fabbri, Psychologist, Behavioral and Mental Health Unit, Joslin Diabetes Center, has no relevant financial relationships.
Dr. Osama Hamdy, Medical Director, Obesity Clinical Program, Joslin Diabetes Center, is on the speakers bureau for Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novo Nordisk Inc., sanofi-aventis U.S., and Takeda Pharmaceuticals North America, Inc.
Karen J. Kuc,* Assistant Director, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
James E. Neighbours,* Associate Director, Education Design, Professional Education, Joslin Diabetes Center, has no relevant financial relationships.
Dr. Robert C. Stanton, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships.
Dr. Howard A. Wolpert, Director of the Insulin Pump Program and Senior Physician, Joslin Diabetes Center is a consultant for Abbott Diabetes Care, Insulet Corporation, Novo Nordisk, Inc. and Becton, Dickinson and Company.
Eyiuche Okeke, MD, has no relevant financial relationships.
*Also a member of the Planning Committee
AMA PRA Category 1 Credit(s)TM
Joslin Diabetes Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Joslin Diabetes Center designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity was planned and produced in accordance with ACCME Essentials. Health professionals not eligible for continuing medical education credit will receive a certificate of participation that they may submit to their state licensing board for credit.
Joslin Diabetes Center designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.